anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine composition for wind-dampness cold type of arthralgia. The raw materials include, by weight, 18-22 parts of radix angelicae tuhuo, 18-22 parts of Pycnostelma sinensis Bge., 13-17 parts of cortex acanthopanacis radicis, 11-13 parts of parasitic loranthus, 11-13 parts of Rhizoma Atractylodis, 8-12 parts of Alpinia katsumadai, 9-11 parts of Piper longum, 7-9 parts of clove, 8-12 parts of Achyranthes bidentata, 9-11 parts of peach kernel, 5-7 parts of safflower, 4-6 parts of herba lycopi, 7-9 parts of fructus aurantii Immaturus, 5-7 parts of fructus liquidambaris, 8-12 parts of spine date seed and 11-13 parts of menthol. The invention also discloses a preparation method of the traditional Chinese medicine composition for wind-dampness cold type of arthralgia. The method is as below: grinding radix angelicae tuhuo, Pycnostelma sinensis Bge. and other raw materials, mixing, conducting ultrasonic treatment, decocting, concentrating, and then adding anhydrous ethanol and menthol to obtain the traditional Chinese medicine composition for wind-dampness cold type of arthralgia. Aiming at the etiology and pathogenesis, the composition employs the means of expelling wind-damp, dispelling cold and dampness and activating blood circulation to eradicate the wind-cold damp evil, and the medication is safe and reliable.
The invention discloses an extraction and separation new method of a silver-yellow formula extract, which pertains to the pharmaceutical field of traditional Chinese medicine. The method firstly mixes baical skullcap root and honeysuckle flower herbal medicines and then carries out decoction extraction, the extract liquid uses ultrafiltration membranes and nanofiltration membranes with the aperture molecular weight of 500000, 100000 and 300 Daltons to carry out the membrane separation, and the substances separated by the membrane with 300 Daltons are finally collected. The solid content is calculated by infrared and high-performance liquid chromatography qualification and quantification. The invention can be used preparing a silver-yellow oral liquor. The method can solve that: (1) when in preparation of the fifth class of new drugs of compound traditional Chinese medicine by the existing preparation process, each Chinese herbal medicine can be separately extracted and prepared; otherwise, the drugs can not meet the standards. The method can achieve the standards of the requirements of the fifth class of the new drugs of the compound traditional Chinese medicine without the independent extraction. (2) The process is simplified, organic solvents and acid-base treatments are unnecessary, the damage on the active ingredients is reduced, and the processing time is shortened by more than 4 times. Therefore, the method solves the problem of environmental pollution, saves the resources and reduces the cost.
BACKGROUND Infection and chronic rejection remain major issues for kidney transplant recipients (KTRs). The present study aimed to explore the association of CD4+/CD8+ T cell ratio (CD4+/CD8+) and platelet/lymphocyte ratio (PLR) with long-term infection and chronic renal insufficiency in KTRs. MATERIAL AND METHODS KTRs admitted to a single hospital from June 2014 to December 2021 were divided into infected (164) and non-infected (107) groups based on clinical data. The levels of CD4+/CD8+, PLR, neutrophil/lymphocyte ratio (NLR), and C-reactive Protein (CRP) in KTRs with long-term infection, and their correlation with chronic kidney insufficiency, were analyzed. Survival analysis was used to evaluate the risk factors for long-term infection and chronic kidney insufficiency. RESULTS Spearman correlation analysis showed that chronic kidney insufficiency was positively correlated with PLR, and negatively correlated with CRP and CD4+/CD8+ (P<0.05). PLR was positively correlated with CRP, procalcitonin, erythrocyte sedimentation rate, and NLR, but negatively with CD4+/CD8+. CD4+/CD8+ was correlated with CRP, NLR, and PLR (P<0.05). Survival analysis and survival curves showed that PLR and CD4+/CD8+ were risk factors for long-term infection and chronic kidney insufficiency in KTRs (P<0.05). CONCLUSIONS CD4+/CD8+ and PLR were associated with long-term complications, and were risk factors for long-term infection and chronic kidney insufficiency in KTRs.
The invention belongs to a health-keeping beverage, in particular to a health-keeping teat of Chinese magnolivine fruit and a preparation method thereof. The contents of the invention by weight share are the following: 8-10 shares of Chinese magnolivine fruit, 75-80 shares of honey, 3-5 shares of snow lotus and 4-7 shares of pilose antlers. The preparation method comprises the process: the Chinese magnolivine after frost falls is dried; the snow lotus and the pilose antlers are dipped into honey and stirred until dissolved; then the dried Chinese magnolivine is added and dipped for 30-48 hours; the dipped Chinese magnolivine is taken out and dried; then the Chinese magnolivine is fried for 10-15 minutes, smashed into small grains and instantly sterilized; at last, sugar with a weight accounting for 20-30 per cent of the total weight of the Chinese magnolivine is added, and the health-keeping tea of Chinese magnolivine is obtained. Besides, the method for processing the health-keeping tea of Chinese magnolivine keeps and fully uses five flavors of the Chinese magnolivine, which are sour, salty, bitter, hot, sweet flavors. At the same time, the invention contains the fragrance of the Chinese magnolivine fruits and is easy for taking. The invention can protect the kidney, enhance the excitement and inhibition process of the central nervous system, improve sleep, promote the ability to remember things, and release fatigue.
Dacarbazine for Injection, USP is a white to an ivory colored solid which is light sensitive. Each 20 mL vial contains 200 mg of dacarbazine, USP (active ingredient). Each vial also contains anhydrous citric acid and mannitol. Dacarbazine for Injection, USP is reconstituted and administered intravenously (pH 3.0 to 4.0). Dacarbazine for Injection, USP is an anticancer agent. Chemically, Dacarbazine for Injection, USP is 5-(3,3-Dimethyl-1-triazeno) imidazole-4-carboxamide (dacarbazine) with the following structural formula:
All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
Disclosed are a group of peptides having an analgesic effect, and a pharmaceutical composition and the use thereof, wherein the peptides have the amino acid sequences as shown in SEQ ID No. 1 or SEQ ID No. 2 in the sequence listing, or pharmaceutically acceptable salts thereof. Also disclosed are polypeptides or pharmaceutically acceptable salts thereof, these still having an analgesic effect after one or more amino acids are deleted, substituted, or added in the amino acid sequences as shown in SEQ ID No. 1 or SEQ ID No. 2 in the sequence listing on the basis of cysteines being present at the N-terminus and C-terminus thereof. Polypeptides are formed after the deletion, substitution, or addition of one or more amino acids in Loop 3 of GsMTx-4, and then, the polypeptides are screened for a polypeptide having an analgesic effect. A short-chain series of polypeptides having an analgesic effect is confirmed by means of test results of the polypeptides with regard to a rat nociceptive pain model.
The preset disclosure provides methods of culturing TILs in a medium comprising at least about 30 mM to at least about 100 mM potassium ion. In some aspects, the methods disclosed herein enhance expansion of CD8 +  TILs, relative to CD4 +  TILs. In some aspects, the methods further increase the number of less-differentiated cells,  e.g. , less-differentiated TILs, in the population of cells. In some aspects, the methods disclosed herein enrich for tumorreactive,  e.g. , tumor specific, TILs such that clonal diversity is preserved. In some aspects, the cells,  e.g. , the TILs, are administered to a subject in need thereof.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to anaesthesiology, and can be used as an anaesthesia care if a surgical delivery in women with severe gestosis is required. For this purpose, at the stage of preanesthetic medication, one of the components is cytoflavin 10 ml dissolved in physiologic saline 200 ml intravenously drop-by-drop for 5 minutes. It is followed by spinal anaesthesia by intrathecal introduction of Marcaine-spinal. After neuroaxial block developed and blood circulation stabilised at average blood pressure reduction by 20 % and less, magnesium sulphate 60 mg/kg is administered intravenously for 15 minutes. Then the operative intervention follows. ^ EFFECT: method allows providing adequate anaesthesia, with prevented potential CNS ischemia and lower development rate and intensity of postoperative arterial hypertension due to the effect on cellular structure metabolism. ^ 6 tbl, 2 ex
Mediterranean diet based on olive oil as main fat and regular consumption of vegetables (2 daily rations), fruits (3 daily rations), legumes (3 weekly rations), fish (3 weekly rations), with low consumption of red meat and meat products (less than twice a week), dairy foods (less than once a week) and no sweets, pastries or sugary drinks. Diet will produce a 600 kcal per day caloric deficit, according to the Harris-Benedict equation for each subject. Diet will include 45% carbohydrates, 35% fat, 20% protein distributed in at least 4 meals (breakfast, lunch, afternoon snack and dinner).
The present invention relates to a simple prescription of an earthworm oral liquid for treating alveolar bone resorption and a preparation method thereof. The earthworm oral liquid is used for treating inflammatory alveolar resorption and other osteoclast-induced bone resorption diseases. The preparation method comprises the steps that earthworm is cleaned, dried, pulverized and mixed with distilled water or 95% alcohol according to the ratio of 1:10(W: V); the mixture is processed by reflux with boiled water and rough filtration; the filtration residue is processed by reflux with boiled water and rough filtration; the two filter liquors are mixed, evaporated and concentrated; when the concentration of a water extracting solution or alcohol extracting solution reaches 1 to 10 kg/L and the content of polysaccharide is more than 10%, the earthworm oral liquid is obtained. As proved by pharmacological experiments by adopting a scleroblast strain MC3T3-E1 of a mouse as a cell model and adopting escherichia coli endotoxin lipopolysaccharide to induce SD rat alveolar bone absorption as an animal model, the earthworm oral liquid has an obvious effect on promoting the proliferation and the differentiation of scleroblast and the mineralization of a substrate and inhibiting alveolar resorption of an animal. Thus, the present invention provides a Chinese herbal medicine preparation for treating alveolar resorption and relevant orthopedics diseases. The preparation method has the advantages of simplicity, convenience, low cost and easy popularization and application.
Asymptomatic hyperuricemia is defined by serum uric acid levels above 6.2 mg/dl in women and 7 mg/dl in men. In the presence of monosodium urate crystal formation and articular inflammation, hyperuricemia may become symptomatic (namely nephrolithiasis and gout). Uric acid results from purine catabolism and is at the centre of a complex metabolic interplay that involves oxidative stress, inflammation, renin-angiotensin-aldosterone system (RAAS) activation and insulin resistance. Uric acid levels present a continuous relation with conditions like hypertension and chronic kidney disease (CKD) and are reported to have an impact on risk of cardiovascular events. However, whether elevated uric acid is a causal agent and thus a possible therapeutic target is still uncertain and matter of further investigation. Treating symptomatic hyperuricemia involves lowering uric acid drugs and controlling inflammation. Urate-lowering agents are well tolerated but show minimal impact on cardiovascular events in patients with gout. Use of direct-acting urate-lowering agents in asymptomatic hyperuricemia associated with cardiovascular diseases does not warrant a clear benefit, whereas addressing cardiovascular issues with guideline-recommended therapies lowers uric acid and reduces the occurrence of cardiovascular events. Regular assessment of uric acid and clinical symptoms is advised before starting and renewing a urate-lowering treatment.
Attention is impaired in many neuropsychiatric disorders, as well as by sleep disruption, leading to decreased workplace productivity and increased risk of accidents. Thus, understanding the neural substrates is important. Here we test the hypothesis that basal forebrain neurons that contain the calcium-binding protein parvalbumin modulate vigilant attention in mice. Furthermore, we test whether increasing the activity of basal forebrain parvalbumin neurons can rescue the deleterious effects of sleep deprivation on vigilance. A lever release version of the rodent psychomotor vigilance test was used to assess vigilant attention. Brief and continuous low-power optogenetic excitation (1 s, 473 nm @ 5 mW) or inhibition (1 s, 530 nm @ 10 mW) of basal forebrain parvalbumin neurons was used to test the effect on attention, as measured by reaction time, under control conditions and following 8 hr of sleep deprivation by gentle handling. Optogenetic excitation of basal forebrain parvalbumin neurons that preceded the cue light signal by 0.5 s improved vigilant attention as indicated by quicker reaction times. By contrast, both sleep deprivation and optogenetic inhibition slowed reaction times. Importantly, basal forebrain parvalbumin excitation rescued the reaction time deficits in sleep-deprived mice. Control experiments using a progressive ratio operant task confirmed that optogenetic manipulation of basal forebrain parvalbumin neurons did not alter motivation. These findings reveal for the first time a role for basal forebrain parvalbumin neurons in attention, and show that increasing their activity can compensate for disruptive effects of sleep deprivation.
Provided is a γδT cell for securing the purity and number of cells sufficient for treatment. Also provided is a method of generating the γδT cell. More specifically, provided are homogeneous γδT cells excellent in that the γδT cells are not affected by exhaustion of the cells. The foregoing is achieved by γδT cells obtained by subjecting induced pluripotent stem cells (iPS cells) to differentiation induction treatment. Specifically, the foregoing is achieved by γδT cells generated by subjecting iPS cells having a rearranged γδTCR gene (γδTCR-type iPS cells) to differentiation induction treatment. According to the method of generating the γδT cell of the present invention, there can be provided γδT cells and a cell population of γδT cells that have an excellent function of having antigen-specific cytotoxic activity in a MHC-unrestricted manner, and that are more homogeneous and have a higher effect than γδT cells separated from peripheral blood.
PURPOSE: A rutin inclusion complex and a cosmetic composition containing the same for anti-aging are provided to ensure excellent cell and collagen proliferation and to be harmless to a human body. CONSTITUTION: A rutin inclusion complex is obtained by including rutin with a cyclodextrin compound. Rutin is isolated from a Chinese Scholar tree, buck wheat, or a mixture thereof. A method for producing the rutin inclusion complex comprises: a step of mixing a rutin-containing ingredient and a cyclodextrin compound aqueous solution to form an inclusion complex; a step of adding an aggregate to the solution containing the inclusion complex to separate the solution and the inclusion complex; and a step of collecting the inclusion complex. The formation of the inclusion complex is performed by stirring the complex at 50-100°C for 5-36 hours. The aggregate is CaCl2, CaSO4, MgCl2, MgSO4, acetic acid, lactic acid, citric acid, oxalic acid, phosphoric acid, nitric acid, hydrochloric acid, or mixture thereof.
This study examined the relative proportion of enteric pathogens associated with severe gastroenteritis (GE) among children younger than 2 years in a phase III efficacy trial of the ROTASIIL® vaccine in India, evaluated the impact of co-infections on vaccine efficacy (VE), and characterized the association between specific pathogens and the clinical profile of severe GE. Stored stool samples collected from cases of severe GE in the phase III trial were tested by quantitative polymerase chain reaction using TaqMan™ Array Cards. Etiology was attributed by calculating the adjusted attributable fraction (AF) for each pathogen. A test-negative design was used to estimate VE. The pathogens with the highest AFs for severe diarrhea were rotavirus (23.5%), adenovirus 40/41 (17.0%), Shigella spp./enteroinvasive Escherichia coli, norovirus GII, enterotoxigenic E. coli, and Cryptosporidium spp. A considerable proportion of the disease in these children could not be explained by the pathogens tested. Severe GE cases associated with rotavirus and Shigella spp. were more likely to have a longer duration of vomiting and diarrhea, respectively. Cases attributed to Cryptosporidium spp. were more severe and required hospitalization. In the intention-to-treat population, VE was estimated to be 43.9% before and 46.5% after adjustment for co-infections; in the per-protocol population, VE was 46.7% before and 49.1% after adjustments. Rotavirus continued to be the leading cause of severe GE in this age group. The adjusted VE estimates obtained did not support co-infections as a major cause of lower vaccine performance in low- and middle-income countries.
Patients receive cobimetinib PO QD on days 1-21 of each cycle, atezolizumab IV over 30-60 minutes on days 1 and 15 of each cycle, and varlilumab IV over 90 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo a CT or MRI at baseline, every 8 weeks while on treatment, and at end of treatment or progression. Patients also undergo a tumor biopsy at baseline and on day 21 of cycle 1. Patients also undergo blood sample collection on study.
Patients assigned to the control group randomly will be re-evaluated 4 weeks after their initial evaluation. No intervention will be applied during this period. After 4 weeks, when the patients are re-evaluated, they will be directed to the appropriate treatment.
NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
Women are given the vaginal microbiome transplant placebo at least one time and up to three times. If the woman receives the transplant more than once, it will be 28 days after the first transplant and again 28 days after the second transplant.
Probiotics exert beneficial effects by regulating the intestinal microbiota, metabolism, immune function and other ways of their host. Patients with constipation, a common gastrointestinal disorder, experience disturbances in their intestinal microbiota. In the present study, we investigated the effectiveness of two microbial ecological agents (postbiotic extract PE0401 and a combination of postbiotic extract PE0401 and Lacticaseibacillus paracasei CCFM 2711) in regulating the makeup of the intestinal microbiota and alleviating loperamide hydrochloride-induced constipation in mice. We also preliminarily explored the mechanism underlying their effects. Both microbial ecological agents increased the abundance of the beneficial bacteria Lactobacilli and Bifidobacterium after administration and were able to relieve constipation. However, the degree of improvement in constipation symptoms varied depending on the makeup of the supplement. The postbiotic extract PE0401 increased peristalsis time and improved faecal properties throughout the intestinal tract of the host. PE0401 relieved constipation, possibly by modulating the levels of the constipation-related gastrointestinal regulatory transmitters mouse motilin, mouse vasoactive intestinal peptide, and 5-hydoxytryptamine in the intestinal tract of the host and by increasing the levels of the short-chain fatty acids (SCFAs) acetic acid, propionic acid, and isovaleric acid. It also increased the relative abundance of Lactobacillus and Bifidobacterium and reduced that of Faecalibaculum, Mucispirillum, Staphylococcus, and Lachnoclostridium, which are among the beneficial microbiota in the host intestine. Furthermore, PE0401 decreased the levels of constipation-induced host inflammatory factors. Therefore, the two microbial ecological agents can regulate the intestinal microbiota of constipation mice, and PE0401 has a stronger ability to relieve constipation.
Patients with a COVID-19 infection at least 3 months ago (positive PCR or rapid antibody test) and PCS typical symptoms (e.g. fatigue, breast pain, heart palpitations, cognitive impairment) ongoing for at least 2 months and which cannot be explained by an alternative diagnosis.
The Gen 3 device will be positioned on the maternal abdomen to measure light scattering and absorption for a period of about 10-20 minutes. A second measurement may be obtained for a total of up to 40 minutes. Subject's end their participation in the study after that time period.
Behavioural sleep problems are very common in children and are concerns for many parents. This review discusses normal sleep physiology and sleep development and focuses on common behavioural sleep problems in childhood, including behavioural insomnia of childhood, parasomnias and sleep-related movement disorders, highlighting their clinical features and management. Behavioural insomnia of childhood is characterised by learned difficulties in falling asleep and/or staying asleep. Management includes establishing bedtime routines and behavioural techniques. Parasomnias include confusional arousals, sleepwalking, sleep terrors and nightmares, and these usually resolve with time. Management includes parental reassurance and behavioural interventions such as scheduled awakening. With regards to sleep enuresis, management includes behavioural modifications, enuresis alarm and desmopressin. Sleep-related movement disorders include sleep-related bruxism and sleep-related rhythmic movements, of which body rocking is the most common. Early identification and management of behavioural sleep problems may prevent their negative impact on children as well as their families.
The data collection will continue consecutively until the goal of 150 patients is reached. If it is feasible, we will try to reach 200 patients. We think 150-200 patients will give good insight into different types of medication discrepancies, since studies have shown that up to 90% of patients have at least one medication discrepancy in primary care.
Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).